Colin Gerard Egan

Dr. Colin Gerard Egan

CE Medical Writing SRLS, Pisa, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MGMarco Galluzzo
Marco Galluzzo
LTLorenzo Tofani
Lorenzo Tofani
PLPaolo Lombardo
Paolo Lombardo
APAlessandra Petruzzellis
Alessandra Petruzzellis
DSDionisio Silvaggio
Dionisio Silvaggio
MTMarina Talamonti
Marina Talamonti
Little information is available from real-life studies evaluating the efficacy of guselkumab in moderate-to-severe psoriasis. In this real-life study, we retrospectively examined a database of 52 patients with moderate-to-severe psoriasis treated with guselkumab (100 mg, s.c.) and followed for 1 year. Disease severity and treatment response was assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 20, 28, 36, 44, and 52 weeks. Predictors of a PASI response were evaluated by univariate and multivariate regression. After 12 months, 84.2% of patients (mean age 51.3 ± 14.1 years) treated with guselkumab achieved a PASI score of <3. Furthermore, PASI score decreased from 20 ± 13.3 at baseline to 4.4 ± 4.7 and 2.7 ± 3.9 at 12 and 20 weeks, and PASI 75, 90, and 100 response was achieved in 84.2%, 78.9%, and 63.2% of patients respectively at 12 months. Stepwise multivariate regression analysis revealed that previous biological treatment and the presence of comorbidities were associated with poorer response between 28–44 weeks, however the presence of obesity per se was not associated with poorer response. Difficult-to-treat areas were also improved as early as 12 weeks following guselkumab. Guselkumab was observed to be effective and safe in patients with moderate-severe chronic psoriasis in a real world-setting.

14 January 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Sandro GianniniSandro Giannini
Sandro Giannini
GPGiovanni Passeri
Giovanni Passeri
GTGiovanni Tripepi
Giovanni Tripepi
SSStefania Stefania Sella
Stefania Stefania Sella
MFMaria Fusaro
Maria Fusaro
FBFrancesco Bertoldo
Francesco Bertoldo
Little information is available on the beneficial effects of cholecalciferol treatment in comorbid patients hospitalized for COVID-19. The aim of this study was to retrospectively examine the clinical outcome of patients receiving in-hospital high-dose bolus cholecalciferol. Patients with a positive diagnosis of SARS-CoV-2 and overt COVID-19, hospitalized from 15 March to 20 April 2020, were considered. Based on clinical characteristics, they were supplemented (or not) with 400,000 IU bolus oral cholecalciferol (200,000 IU administered in two consecutive days) and the composite outcome (transfer to intensive care unit; ICU and/or death) was recorded. Ninety-one patients (aged 74 ± 13 years) with COVID-19 were included in this retrospective study. Fifty (54.9%) patients presented with two or more comorbid diseases. Based on the decision of the referring physician, 36 (39.6%) patients were treated with vitamin D. Receiver operating characteristic curve analysis revealed a significant predictive power of the four variables: (a) low (<50 nmol/L) 25(OH) vitamin D levels, (b) current cigarette smoking, (c) elevated D-dimer levels (d) and the presence of comorbid diseases, to explain the decision to administer vitamin D (area under the curve = 0.77, 95% CI: 0.67–0.87, p < 0.0001). Over the follow-up period (14 ± 10 days), 27 (29.7%) patients were transferred to the ICU and 22 (24.2%) died (16 prior to ICU and six in ICU). Overall, 43 (47.3%) patients experienced the combined endpoint of transfer to ICU and/or death. Logistic regression analyses revealed that the comorbidity burden significantly modified the effect of vitamin D treatment on the study outcome, both in crude (p = 0.033) and propensity score-adjusted analyses (p = 0.039), so the positive effect of high-dose cholecalciferol on the combined endpoint was significantly amplified with increasing comorbidity burden. This hypothesis-generating study warrants the formal evaluation (i.e., clinical trial) of the potential benefit that cholecalciferol can offer in these comorbid COVID-19 patients.

2 October 2018 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
LBLuca Bianchi
Luca Bianchi
RCR. D. Caposiena Caro
R. D. Caposiena Caro
GGG. Ganzetti
G. Ganzetti
EME. Molinelli
E. Molinelli
VDValentina Dini
Valentina Dini
AOA. M. Offidani
A. M. Offidani

1 May 2012 in Vascular Health and Risk Management
Verified
Journal Article
Open access
CEColin Gerard Egan
Colin Gerard Egan
GLGastone Leonetti
Gastone Leonetti
Peer reviewed article authored by (Leonetti G, Egan CG). Read article or submit your manuscript for publishing.

30 October 2019 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
MGMarco Galluzzo
Marco Galluzzo
SDS. D’aDamio
S. D’aDamio
DSDionisio Silvaggio
Dionisio Silvaggio
PLP. Lombardo
P. Lombardo
AMA. Massaro
A. Massaro
MTMarina Talamonti
Marina Talamonti
Background: Limited information is available from real-life studies evaluating the long-term efficacy and drug retention of ustekinumab. Research design and methods: Data from 378 patients with moderate-severe psoriasis were retrospectively analysed. Over 8 years, disease severity and treatment response were evaluated using the PASI score. Predictors of PASI response were evaluated by logistic regression. Ustekinumab retention rate was calculated by the Kaplan-Meier method. Results: Over the 8 years, >80% of patients achieved a PASI score of <3 and PASI 75, 90 and 100 response was achieved in 76.2%, 61.9% and 57.1% of patients respectively. Predictor variables for improved PASI response (after 2 years) were HLA-C*06-POS patients, female gender and BMI <30 Kg/M2. The 2-year retention rate was 81% and 59% after 8 years with mean retention rate of 5.4 years. Improved retention rate was observed in patients positive for the HLA-C*06 allele (3.7 vs. 2.5 years, p=0.005) and female gender (3.7 vs. 3.3 years, p=0.06), with no significant difference observed in other patient groups. Ustekinumab was generally well tolerated without evidence of cumulative toxicity or organ toxicity. Conclusion: The long-term use of ustekinumab was observed to be effective and safe in patients with moderate-severe chronic psoriasis in a real world-setting.

Verified
Journal Article
Open access
PDF file
Teresa GriecoTeresa Grieco
Teresa Grieco
Giovanni PaolinoGiovanni Paolino
Giovanni Paolino
EMElisa Moliterni
Elisa Moliterni
CCCamilla Chello
Camilla Chello
ASAlvise Sernicola
Alvise Sernicola
SCStefano Calvieri
Stefano Calvieri
Vitamin D is increasingly recognized as a key regulator of epithelial barrier integrity and mucosal immune homeostasis, with implications extending far beyond skeletal health. Through the vitamin D receptor (VDR), vitamin D regulates epithelial cohesion, innate immune responses, and tight-junction gene expression. This review explores the multifactorial role of vitamin D in modulating inflammation and preserving tissue barriers, with particular emphasis on its effects on tight junction (TJ) regulation and disease states characterized by barrier dysfunction, namely atopic dermatitis, psoriasis, inflammatory bowel disease (IBD), and celiac disease. In these settings, vitamin D/VDR signaling exerts protective actions by enhancing barrier structure, suppressing Th1/Th17-driven inflammation, modulating the gut and skin microbiome, and promoting epithelial repair. Animal studies and clinical data suggest that vitamin D supplementation can restore TJ expression, reduce disease activity, and improve clinical outcomes in both intestinal and dermatologic diseases. In the cardiovascular system, the role of vitamin D remains complex. While vitamin D influences endothelial function, insulin sensitivity, and systemic inflammation, supplementation trials yield mixed results, indicating a need for individualized approaches. Overall, this review synthesizes mechanistic, translational, and clinical data supporting vitamin D as a crucial modulator of barrier integrity and inflammation. These findings highlight its therapeutic relevance in chronic diseases characterized by immune dysregulation and epithelial disruption.